Introduction
Acute erythroleukemia (AML-M6) was first described in 1912 by Copelli, 1 but it was Di Guglielmo 2 who coined the term 'eritroleucemia', describing an abnormal proliferation of erythroid cells, myeloblasts and megakaryocytes. 3 In 1923 Di Guglielmo 4 described a case of pure erythroleukemia characterized by pure proliferation of erythroid immature elements, akin to acute leukemia. In 1953 Dameshek proposed the term 'Di Guglielmo's Syndrome', which described three phases of alterations in the bone marrow (BM): an erythremic phase, an erythromyeloblastic phase and a myeloblastic phase, similar to acute myeloid leukemia (AML). 5 The French-American-British classification of AML in 1976 established the first set of criteria for the diagnosis of AML-M6. 6 A revision of the French-American-British classification defined AML-M6 as the presence of more than 50% erythroid cells with more than 30% blasts among non-erythroid BM nucleated cells. 7 The World Health Organization (WHO) classification recognizes the French-American-British entity (mixed myeloid/ erythroid (AML-M6a), but with the lower blast threshold of 20%) plus the entity known as pure erythroleukemia (AML-M6b), when more than 80% of BM cells are immature cells (with an undifferentiated or pro-normoblastic appearance) committed exclusively to the erythroid lineage. 8 AML-M6 has been considered to be a subtype of AML with a worse prognosis. [9] [10] [11] [12] [13] It is very uncommon in children, 14, 15 and it corresponds to 3-5% of adult AML cases. 12 Familial and congenital forms have been described. 16, 17 It is often associated with an antecedent diagnosis of myelodysplastic syndrome (MDS) and the presence of poor-risk chromosome abnormalities. 9, [18] [19] [20] Owing to its rarity, the clinical experience with AML-M6 is limited. It is also not clear if the pathological diagnosis of AML-M6 is associated with a worse prognosis or if the worse prognosis reported with this leukemia is because of its frequent association with poor-risk karyotype and other poorrisk features.
The objective of this study is to describe the clinical and biological features of patients with AML-M6 treated at the University of Texas-M.D. Anderson Cancer Center (UT-MDACC) and to compare them with patients with non-M6 AML. We also evaluated the impact of a diagnosis of AML-M6 in response rate and survival independent of other risk factors.
Patients and methods

Patients
Adult patients with newly diagnosed AML-M6 seen at UT-MDACC between 1 January 1980 and 21 May 2008 were compared with patients with other AML subtypes, excluding those with acute promyelocytic leukemia. Charts were manually reviewed. Patients were treated on studies conducted at UT-MDACC. Studies were approved by the Institutional Review Board and conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent before study entry. A diagnosis of AML-M6a (mixed erythroid/myeloid) was considered if more than 50% of the total nucleate BM cells were of erythroid lineage and more than 20% of non-erythroid cells were blasts.
8 AML-M6b (pure erythroleukemia) was diagnosed in patients who presented with more than 80% of BM nucleate cells consisting of immature erythroid precursors. 8 On the basis of previous reports of similar cases we also considered a diagnosis of AML-M6b in patients who presented with acute undifferentiated leukemia with blasts that were positive by immunophenotyping for glycophorin A, even though these cases did not fit the current WHO criteria. [21] [22] [23] [24] Also of importance, no patient had received erythropoietin at the time of BM aspiration for the diagnosis to be confirmed. Pathology reports of BM biopsies were reviewed for information about dysplasia in one or more hematopoietic lineages. Cytogenetic data was stratified into three subgroups (modified from previous reports [25] [26] [27] ): Poor-risk (À5, À7, þ 8 and 11q involvement and complex karyotype), good-risk (t(8;21) or Inv(16) t(16;16)) and intermediate-risk (neither good nor poor ). Patients received different treatment regimens according to the period of diagnosis and prevailing studies. The treatment regimens were divided into: Group 1, regimens with cytarabine (ara-C) and anthracyclines. Group 2, regimens with ara-C and fludarabine without anthracyclines. Group 3, regimens with ara-C plus topotecan. Group 4, other ara-C containing regimens. Group 5, miscellaneous non-ara-C containing intensive chemotherapy regimens.
Criteria for response and survival, and statistical analysis Complete remission (CR) was defined by the presence of o5% blasts in the BM with more than 1 Â 10 9 /l neutrophils and more than 100 Â 10 9 /l platelets in the peripheral blood. 28, 29 A relapse was defined by more than 5% blasts in a BM aspirate unrelated to recovery or by the presence of extramedullary disease. Disease-free survival (DFS) was calculated from the time of CR until relapse or death in CR. Event free survival (EFS) was calculated from the beginning of treatment until an event. An event was defined as relapse, resistant disease and death. Induction death was defined as death occurring before achievement of CR or confirming resistant disease. Overall survival (OS) was calculated from the time of diagnosis until death. All patients alive at last follow-up were censored. Categorical and continuous variables were compared by the w 2 /Fischer's exact test and Mann-Whitney U test, respectively.
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The survival curves were estimated using Kaplan-Meier plots and compared by the log-rank test. 31 Multivariate logistic regression models were used to evaluate the associations between multiple characteristics and diagnosis of AML-M6 or achievement of CR. Clinical and biological characteristics were analyzed for their association with survival using multivariate Cox proportional hazards models. 32 All the univariately significant variables are included in a multivariate model, and then stepwise variable selection was done. For white blood cell count (WBC), platelets and lactate dehydrogenase (LDH), as some patients had extremely large values, the variables were grouped into four quantiles. In stepwise selection, if any of the group variables was significant, then all the other groups were included in the final model even though some variables may have P-values larger than 0.05. The survival analysis for stem cell transplantation (SCT) for AML-M6 patients was done with a multivariate Cox proportional hazards model with transplant status used as a time-dependent covariate (predictor). This analysis automatically matches patients who received SCT with patients who did not receive SCT on the selected prognostic factors, and requires each non-SCT match to live, at least, long as the time to SCT for his/her pairmate. All computations were done in SAS (Cary, NC, USA) and Statistica, version 6.0 (Tulsa, OK, USA).
Results
Clinical and biological features
There were 2992 patients with newly diagnosed AML seen at the UT-MDACC during the specified period, and 108 were diagnosed as having AML-M6. Among these 108 patients, 78 had diagnostic criteria consistent with AML-M6a. Of the remaining 30 patients, 5 patients had diagnostic criteria for AML-M6b (more than 80% of BM cells consisted of immature erythroid precursors) and 8 patients did not fulfill the criteria for AML-M6b but presented with undifferentiated leukemia with blasts positive for glycophorin A. The remaining 17 patients were diagnosed as having AML-M6 in our institution, on the basis of morphology and/or positivity for periodic acid Schiff (PAS) stain, but as they did not fulfill the current criteria for this disease, they were excluded from this analysis. All these 17 patients were diagnosed before the current WHO criteria were defined. Thus, 91 patients remained for our analysis, corresponding to 3.0% of all patients with AML. There was a higher proportion of patients with AML-M6 diagnosed in the decades of 1990 and 2000, probably a reflection of the advances in immunophenotyping and establishment of diagnostic criteria for this entity: there were 6 (1%) of 612 patients during 1980-1989, 34 (3.1%) of 1087 patients during 1990-1999 and 51 (3.9%) of 1276 patients from 2000-2008 (P ¼ 0.002). This can also be an artifact because we excluded 17 patients who were diagnosed in the time period from 1980 until 1999, when the WHO criteria for AML-M6b were not established. The clinical features of patients with AML-M6 are summarized in Table 1 . They were different from patients with other AML subtypes in a number of characteristics. There was a male predominance (68% versus 55%, P ¼ 0.02), a slightly higher prevalence of antecedent hematological disorder (AHD)/MDS (50% versus 41%, P ¼ 0.08) and more frequent finding of dysplastic changes in BM cells (80% vs 50%, Po0.001). They also had, at presentation, lower hemoglobin levels (Po0.001), lower WBC count (Po0.001), lower platelet count (Po0.001) and a higher prevalence of poor-risk cytogenetic abnormalities (61% versus 38%, Po0.001). All variables significantly associated with AML-M6 in Table 1 were fitted into a logistic regression model to predict the diagnosis of AML-M6. As data was lacking in a substantial proportion of patients for BM dysplasia and b2-microglobulin, these variables were not included into the model. In the final model, the following covariates predicted for the diagnosis of AML-M6: intermediate-risk karyotype (versus good-risk), poor-risk karyotype (versus good-risk), lower percentage of BM blasts and lower WBC (Supplementary Table 1S ). The year of diagnosis was not a predicting factor for the diagnosis of AML-M6.
In all, 78 patients with AML-M6 (86%) had AML-M6a. The median number of erythroblasts was 60% (43-87%). One case had 43% erythroblasts on the BM aspirate, but sheets of immature erythroblasts were seen on BM biopsy. The median number of myeloid blasts (of non-erythroid cells) was 45% (range 19-90.3%). One case had 19% blasts seen on aspirate, but the number of immature myeloid cells was estimated to be 30% by the biopsy. Thirteen patients (14%) presented with AML-M6b. The median number of erythroid blasts was 60% (30-86.6%). Eleven patients were tested for glycophorin A; it was positive in 10 (91%). The PAS stain was carried out in 67 patients (AML-M6a and AML-M6b) and was positive in 58 cases (87%). One patient was positive for CD36 and in one case the diagnosis was confirmed by electron microscopy. Among the 13 patients with a diagnosis of AML-M6b, 10 (77%) had concordance of diagnosis by morphology, cytochemistry and flow cytometry. In two patients the diagnosis was established on morphological grounds (480% erythroblasts) and cytochemistry (globular PAS-positivity) (flow cytometry was not carried out in these patients) and in one case the diagnosis was established based on morphology and flow cytometry (glycophorin-A positivity), with negative PAS.
In all, 45 patients (50%) had a previous history of MDS or other AHD. A minimum period of 4 weeks with abnormal blood counts was needed for a diagnosis of AHD. Forty-one (45%) patients had MDS and/or cytopenias, with a median duration of 5 months (1-72) before the diagnosis of AML-M6. Three patients had a previous diagnosis of myeloproliferative disorder (one patient with polycythemia vera, one with essential thrombocythemia and one with both polycythemia vera and MDS), and one patient had chronic lymphocytic leukemia as well as MDS. A total of 17 patients had previously received chemotherapy and/or radiation therapy, and two additional patients had a history of solid tumors, but had only received surgical treatment.
Cytogenetic data was available for 90 patients (98%) (one case had insufficient metaphases). Cytogenetic abnormalities were detected in 61 patients (68%). The most common cytogenetic abnormality was a complex karyotype, present in 49 patients (54%), including 40 (44%) patients who presented with abnormalities of chromosomes 5 and/or 7. Isolated trisomy 8 was present in 5.5% of cases. No patient with AML-M6 presented with good-risk cytogenetics. There were four patients (4.4%) with 19q13 abnormalities, including one translocation t(11;19)(q11;q13.3). All of these patients had complex karyotypes.
Treatment response and survival
Patients were treated using different regimens of intensive induction chemotherapy, according to the time of diagnosis and the prevailing protocols (Table 1 ). There was no significant difference in the proportions of patients with AML-M6 and non-M6 AML in the different treatment groups (P ¼ 0.45).
Response and survival outcomes for all patients are summarized in Table 2 and Figure 1 . The median follow-up for the entire cohort is 321 weeks. The CR rate for AML-M6 was 62% (versus 58% for non-M6 AML, P ¼ 0.35). In all, 18 patients with AML-M6 were refractory (20%) and 16 (18%) patients died at induction. All characteristics in Table 1 were evaluated for their Table 2 . 
Prognostic factors associated with survival
By univariate analysis, the following factors were associated with worse DFS: older age, intermediate risk-cytogenetics, poor-risk cytogenetics, lower hemoglobin, lower platelets, poor performance status, history of AHD/MDS and previous chemotherapy/ radiation therapy. Treatment group 2 was associated with better DFS on univariate analysis. Prognostic factors associated with a worse DFS by multivariate analysis are in Table 3 . The diagnosis of AML-M6 was not an independent predictive factor for worse DFS (HR 1.07; P ¼ 0.64). No treatment group was predictive of worse DFS by multivariate analysis.
The following factors were associated with worse OS by univariate analysis: diagnosis in the 1980s, older age, intermediate-risk cytogenetics, poor-risk cytogenetics, lower hemoglobin, WBC 433.3 Â 10 9 /l, low platelets (o27 Â 10 9 /l) and high platelets (489 Â 10 9 /l), high LDH (4904 IU/l), poor performance status, history of AHD/MDS, history of previous chemotherapy and treatment group 5. Prognostic factors associated with a worse OS by multivariate analysis are summarized in Table 4 . The diagnosis of AML-M6 was not an independent predictive factor for worse OS (HR 1.03; P ¼ 0.76).
Discussion
In this report we analyzed the clinical and laboratory characteristics and survival outcomes of 91 patients with AML-M6 and compared them with other patients with AML diagnosed and treated during the same period. Patients were treated with several different regimens, but there was no significant imbalance in treatment group distribution, and thus we did not stratify our results by therapy. There was no difference in CR rate, but in a multivariable analysis a diagnosis of AML-M6 was associated with a higher probability of achieving CR. This is surprising in view of the association between AML-M6 and other poor risk features that usually lead to lower response rates. However, because of its retrospective nature, these results must be considered with caution. In addition, most patients were treated with ara-C and received higher doses than what is conventionally used (1.5 g/m 2 per day), and a high percentage of patients with AML-M6 (64%) received induction chemotherapy inside protected environment rooms; a higher percentage than what is commonly found in other institutions. These limitations might affect the validity and general applicability of these results. Despite being associated with the achievement of CR, there was a worse DFS for patients with AML-M6 compared with other subtypes of AML. The EFS and OS were also shorter for patients with AML-M6, but this was not statistically significant. However, our study may have been underpowered to detect such differences. In the multivariate analysis for DFS, the diagnosis of AML-M6 was not an independent prognostic factor. Thus, patients with AML-M6 had a worse prognosis due to the frequent association of this subtype of AML with other poor-risk features (such as monosomal karyotypes and history of MDS).
Other case series of adult AML-M6 are summarized in Table 5 . 11, 19, 33 Our series confirm some of the findings in previous reports. The presence of pancytopenia, with low circulating blasts is typical of AML-M6, with very few patients presenting with elevated WBC (only six patients in our series had WBC more than 12 Â 10 9 /l). No recurrent chromosomal abnormalities have been reported. Abnormalities of chromosome 5 and/or 7 with a complex karyotype were the most common cytogenetic aberration detected in our series, as well as in previous reports. 9, 18, 20, 34 A recent study reported a high rate (10%) of chromosome 19 aberrations, in band 19q13. 35 Four patients in our series had abnormalities of chromosome 19 at the same band, confirming this data. In our series we fitted a multivariate logistic regression model to evaluate characteristics associated with a diagnosis of AML-M6. The OR for a diagnosis of AML-M6 decreased with an increase in WBC (OR 0.03 for WBC 433.3 Â 10 9 /l, P ¼ 0.0016) and increased in the presence of poor-risk karyotype (OR 16.09, P ¼ 0.006).
What can be gleaned from our study and previous reports is that most cases of AML-M6 are strongly related to MDS, with patients usually presenting with a previous history of MDS or with de novo AML with MDS-like clinical features, including pancytopenia, unbalanced chromosomal abnormalities and dysplastic morphology. The increase in both myeloid blast cells and erythroblasts in AML-M6a indicates the involvement of an early stem cell in the pathogenesis of this disease. Previous reports have demonstrated multilineage involvement in cases of AML-M6a, with the presence of a myelomonocytic and megakaryocytic component besides the erythroid component. 34 Thus, it could be argued that AML-M6a is a clonal myeloid disorder similar to MDS that has multilineage involvement and presents with a major erythroid component, whereas AML-M6b represents a 'true erythroleukemia', where only erythroid cells are involved in the malignant clone. 36 In our cohort we found 13 patients with a diagnosis of pure erythroleukemia. Not all patients that were diagnosed as AMLM6b in our series fulfilled the WHO criteria, 8 as 8 patients had less than 80% immature erythroblasts in the BM, but were nonetheless considered as having AML-M6b based on positivity for glycophorin A, a specific red cell marker, which can also be negative in some cases of AML-M6. 24 The erythroblast threshold of the WHO criteria for AML-M6b is arbitrary, and several cases of AML-M6b may be missed by setting such a high threshold for diagnosis, as has already been reported by others. 37 In our cohort, patients with AML-M6b commonly had dysplastic features in the erythroid series and were usually positive for the PAS stain in blast cells. PAS is not specific for AML-M6, and can be positive in other leukemias including acute lymphoblastic leukemia. 38 However, the presence of coarse block-like PAS staining in blasts with absence of other lineage-specific markers (such as MPO and TdT) is suggestive of AML-M6. 19, 37, 39 The role of allogeneic SCT in AML-M6 has been the subject of two reports which suggest that allogeneic SCT should be offered to all patients with AML-M6 in first CR. 40, 41 In our report, patients with AML-M6 who underwent allogeneic SCT had longer EFS and OS compared with patients who did not receive an allogeneic SCT. However, patients who received an allogeneic SCT were younger, and this suggests possible selection biases in these results. In a multivariate model analyzing SCT as a time-dependent covariate there was no effect of transplant in OS. Nevertheless, allogeneic SCT should be considered in patients with AML-M6 who present with other poor-risk features.
In conclusion, AML-M6 is a rare subtype of AML that is frequently related to MDS. Our results confirm the importance of classical AML prognostic factors in the outcome of patients with AML-M6. The pathological diagnosis of AML-M6 does not impart by itself a worse outcome. Thus, even though the FrenchAmerican-British classification has historical significance, in general clinicians should refrain from making treatment decisions based on morphological grounds alone for patients with AML-M6. Instead, they should rely on cytogenetics and other prognostic features when deciding the best therapeutic approach.
